ABSTRACT. Objective. We aimed to establish the prevalence and clinical associations of anti-HMG-CoA-reductase (anti-HMGCR) in a large UK cohort with juvenile myositis. Methods. There were 381 patients investigated for anti-HMGCR using ELISA.
Necrotizing autoimmune myopathy (NAM) is a subgroup of the idiopathic inflammatory myopathies that is defined by common clinical and histopathological features. Patients present with high creatinine kinase (CK) levels and often profound weakness. On muscle biopsy, characteristic features include myofiber necrosis, minimal endomysial, and perivascular inflammatory infiltrate, and in some cases focal endomysial fibrosis 1 . Despite little or no muscle inflammation, NAM usually responds to immunomodulatory therapy, highlighting that this is an immune-mediated phenotype. It has been associated with 2 myositis-specific autoantibodies: antisignal recognition peptide (anti-SRP) and more recently anti-HMG-CoA-reductase (HMGCR).
Patients with anti-HMGCR-associated disease make up about 6% of adult idiopathic inflammatory myopathy cohorts 2 . In addition to NAM, anti-HMGCR antibodies are associated with statins, an intriguing finding given that HMGCR is the pharmacologic target of statins and is upregulated by statin use 2 . While statins are typically prescribed to adult patients, anti-HMGCR has been reported in patients with juvenile-onset NAM, but data are extremely limited 3 . Further, 40%-70% of adults with anti-HMGCR-associated NAM have no history of statin exposure, suggesting the presence of alternative disease triggers 2, 3 . We aimed to establish the prevalence and clinical associations of anti-HMGCR in a large UK juvenile idiopathic inflammatory myositis (JIIM) cohort.
MATERIALS AND METHODS
Patients. Serum samples and matched clinical data were obtained from 381 patients with JIIM recruited to the UK Juvenile Dermatomyositis Cohort and Biomarker Study described previously 4 . Ethical approval has been obtained (Northeast-York Research Ethics Committee 01/3/022). Parental consent and consent or age-appropriate assent was obtained in accordance with the Declaration of Helsinki.
Autoantibody detection. Immunoprecipitation of all samples was performed to determine the presence of myositis-specific and -associated autoantibodies, as previously described 5, 6 . The presence of anti-HMGCR was determined in all samples by ELISA using recombinant antigen, as previously described 7 . Positive samples were confirmed by Western blotting (insufficient serum for patient 3). A further 48 juvenile healthy controls, 21 patients with juvenile systemic lupus erythematosus, and 27 muscular dystrophy were found to be negative for anti-HMGCR.
Immunofluorescence. Human epithelial cell line 2 indirect immunofluorescence was performed at 1:40 serum dilution for all anti-HMGCR-positive samples according to the manufacturer's instructions (Inova). Muscle biopsy. Where tissue was available for reassessment, muscle biopsies were processed, stained, and scored (using the International Juvenile Dermatomyositis score tool) by an expert pediatric neuropathologist (TSJ) blinded to clinical data 8, 9 .
RESULTS
Anti-HMGCR autoantibodies were detected in 4 of the 381 patients (1%). None had a history of statin exposure. Anti-HMGCR autoantibodies were not found in conjunction with any other myositis-specific or -associated autoantibody. All patients with anti-HMGCR had a cytoplasmic staining pattern on immunofluorescence, and 2 had additional coarse speckled nuclear staining.
While numbers were insufficient for statistical analysis, based on Childhood Myositis Assessment Scores (CMAS) and the physician's global assessment of disease activity visual analog scores (PGA), children with anti-HMGCR were weaker and had greater disease activity (Table 1) . Consistent with previous reports in juvenile-onset disease, CK at presentation was elevated in just 55.4% of patients 10, 11 . Of those patients with an elevated CK, the median value was 1039 IU/l (415-4115.25), compared with 15,500 (12,000-25,250) for those with anti-HMGCR. Patient 1. A 4-year-old girl developed a relatively slow-onset muscular weakness with a lowest-ever CMAS of 28 (0-53), corresponding to a moderate degree of weakness 12 . CK at presentation was 12,000. She had no rash. Muscle biopsy was reported to be consistent with dermatomyositis (DM). Her highest-ever PGA was 4.8 out of 10. She responded to initial treatment with oral methotrexate (MTX) and steroids, but CK remained elevated. Her disease flared (lowest CMAS of 33 with no rash and peak CK of 7000) when MTX was stopped after a lengthy period of remission, following which treatment was restarted with subcutaneous MTX alongside oral prednisolone (PRED). She subsequently responded to infliximab (IFX) and entered remission. Patient 2. A 13.8-year-old girl presented with periorbital puffiness and hyperpigmentation with progressive weakness over 1-2 months. Her CK was found to be 44,000. She received pulsed intravenous (IV) methylprednisolone with some improvement. Muscle biopsy revealed a destructive myopathy with inflammation and necrosis. One month later, her CMAS score was 0, indicating very severe weakness. She required nasogastric feeding. She received further pulses of IV methylprednisolone, cyclophosphamide (CYC), and subcutaneous MTX. Improvement in muscle power was extremely slow, leading to concern that there may be an additional underlying muscle disease. Further investigations, including magnetic resonance imaging (MRI), electromyography, and nerve conduction studies were consistent with myositis. This patient was subsequently treated with azathioprine, rituximab (RTX), and further CYC before entering remission with IFX. Table 2 . The biopsies had similar and distinctive features with widespread variation in fiber size, regenerating fibers, necrotic fibers, and degenerating fibers. There were frequent fibers expressing immature isoforms of myosin and deposition of the membrane attack complex (MAC; C5b-C9) on the sarcolemma of many fibers. There were patchy dense 3 
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Personal non-commercial use only. The Journal of Rheumatology Copyright © 2017. All rights reserved. Table 2 . Muscle biopsy score breakdown for patients with anti-HMGCR. Biopsy appearances were consistent with a destructive myopathy with high scores in the muscle fiber domain. All biopsies had evidence of inflammation. Muscle biopsies were analyzed using the JDM muscle biopsy score tool as previously described by Wedderburn, et al 8, 9 . infiltrates of chronic inflammatory cells within the fascicles (Figure 1 ).
Variables

DISCUSSION
Consistent with previous reports, patients with anti-HMGCR presented with either profound or insidious onset muscle weakness 3 . Unlike affected adults, however, half of our patients had cutaneous disease 2, 3 . Lack of skin involvement is unusual in JIIM and minimal/absent rash contributed to the need to actively exclude alternative diagnoses in those with anti-HMGCR. Remarkably, all children with anti-HMGCR underwent muscle biopsy and 2 electromyography; these invasive procedures are not routinely used diagnostically in the United Kingdom for suspected JIIM, the majority of patients being diagnosed on the basis of clinical features plus laboratory and MRI results. Muscle biopsies were distinctive and features included those previously reported by Allenbach, et al, with muscle fiber necrosis and degeneration/regeneration 3 . Contrary to previous reports of a pauciimmune necrotizing myopathy, however, there was evidence of inflammation in all 4 biopsies. JIIM muscle biopsies can display a wide range of changes that may not necessarily be considered "typical" of DM. All patients with anti-HMGCR had an abnormal muscle biopsy with a pattern of histological features that, while not classic for DM, was consistent and distinctive. Recognition of this phenotype is important to ensure that muscle biopsy can provide the maximum level of diagnostic accuracy. Earlier recognition of anti-HMGCR autoantibodies may aid diagnosis, prevent potentially unnecessary investigations, and facilitate rapid treatment escalation in the absence of a good response to standard therapy. Mammen, et al confirmed the absence of anti-HMGCR in patients with genetic muscle diseases that often form the differential diagnosis 13 .
While rare, anti-HMGCR identify an important group of JIIM patients with severe disease necessitating aggressive treatment. In the United Kingdom, strict guidelines exist for funding biologic treatments, and it is remarkable that all 4 cases ultimately received this; in comparison with just 20.7% of the total cohort. We noted similarities in disease presentation to those patients with anti-SRP autoantibodies, in whom muscle weakness is also greater and cutaneous disease less common. Less than one-third of patients with anti-SRP, however, required treatment with a biologic drug and/or IV CYC. It is interesting to note that while statinexposed adult patients with anti-HMGCR are reported to respond dramatically to treatment, statin-naive patients have been noted to be younger, and may be refractory to immunosuppressive therapy 2, 14 . Younger, statin-naive patients with anti-HMGCR may represent a separate subgroup of patients who are less responsive to treatment. These data suggest that in those children with anti-HMGCR and severe weakness, there is an argument for the early use of aggressive immunosuppression.
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The Muscle biopsy features of patients with anti-HMGCR autoantibodies. All 3 biopsies showed a similar distinctive pattern of pathology characterized by widespread variation in fiber size, regenerating fibers, necrotic fibers, and degenerating fibers with vacuoles and ill-defined eosinophilic granules (A-C). The abnormal fibers were present throughout all the fascicles with no perifascicular accentuation. There were patchy dense infiltrates of chronic inflammatory cells within the fascicles. The infiltrate showed a prominent component made up of T lymphocytes (D; CD3). There were fewer inflammatory cells in the perimysium. In all 3 cases, many of the fibers expressed a developmental isoform of myosin (E; NEO). Staining for the MAC (C5b-9) of the complement cascade highlighted necrotic fibers, but also outlined the sarcolemma of many of the non-necrotic fibers (F). Capillary deposition of MAC was not seen. Scale bars-100 µm. Anti-HMGCR: anti-HMG-CoA-reductase; NEO: neonatal myosin; MAC: membrane attack complex.
